Selecta Biosciences, Inc.
(NASDAQ : SELB)

( )
SELB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.12%283.741.5%$847.25m
GILDGilead Sciences, Inc. 0.98%86.261.0%$795.01m
MRNAModerna, Inc. -0.23%176.400.0%$769.19m
VRTXVertex Pharmaceuticals, Inc. -1.01%312.981.9%$482.01m
REGNRegeneron Pharmaceuticals, Inc. 0.12%736.232.6%$473.28m
BIIBBiogen, Inc. 0.56%305.151.8%$355.07m
ILMNIllumina, Inc. -1.39%218.993.2%$270.73m
SNSSSunesis Pharmaceuticals, Inc. 5.70%2.780.7%$194.33m
BMRNBioMarin Pharmaceutical, Inc. -0.89%96.924.2%$161.47m
BNTXBioNTech SE -0.88%154.850.0%$152.12m
MRTXMirati Therapeutics, Inc. 2.89%98.621.6%$132.21m
TECHBio-Techne Corp. 0.79%338.974.5%$123.89m
AXSMAxsome Therapeutics, Inc. 1.07%56.821.6%$80.71m
NVAXNovavax, Inc. -2.88%16.5475.3%$70.44m
HALOHalozyme Therapeutics, Inc. 0.59%54.6718.4%$64.50m

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.